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Curcumin, the bioactive component of turmeric also known as “Indian Yellow Gold,” 
exhibits therapeutic efficacy against several chronic inflammatory and infectious dis-
eases. Even though considered as a wonder drug pertaining to a myriad of reported 
benefits, the translational potential of curcumin is limited by its low systemic bioavail-
ability due to its poor intestinal absorption, rapid metabolism, and rapid systemic 
elimination. Therefore, the translational potential of this compound is specifically chal-
lenged by bioavailability issues, and several laboratories are making efforts to improve 
its bioavailability. We developed a simple one-step process to generate curcumin 
nanoparticles of ~200 nm in size, which yielded a fivefold enhanced bioavailability in 
mice over regular curcumin. Curcumin nanoparticles drastically reduced hepatotoxic-
ity induced by antitubercular antibiotics during treatment in mice. Most interestingly, 
co-treatment of nanoparticle-formulated curcumin along with antitubercular antibiotics 
dramatically reduced the risk for disease reactivation and reinfection, which is the major 
shortfall of current antibiotic treatment adopted by Directly Observed Treatment Short-
course. Furthermore, nanoparticle-formulated curcumin significantly reduced the time 
needed for antibiotic therapy to obtain sterile immunity, thereby reducing the possibility 
of generating drug-resistant variants of the organisms. Therefore, adjunct therapy of 
nano-formulated curcumin with enhanced bioavailability may be beneficial to treatment 
of tuberculosis and possibly other diseases.
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inTrODUcTiOn
Tuberculosis (TB) remains a major global health problem that claims ~2 million lives and causes 
9.6 million infections every year (1). More than 90% of people exposed to Mycobacterium tubercu­
losis (M.tb) remain asymptomatic throughout their life, and only ~10% display active TB disease, 
especially when exposed to profound immune perturbation such as during infection with human 
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immunodeficiency virus, treatment with immune-suppressive 
drugs, and in diseases such as diabetes that are associated with 
immune deficiency (2–4). In the majority of infections, the 
immune system is sufficient to confine the harbored organisms 
within organized cellular structures called granulomas and 
establish latent infection (2–4). The vast majority of infected 
individuals successfully eliminates the harbored M.tb organisms 
and remains resistant to TB throughout life (5, 6). Taken together, 
these observations suggest that the immune system can effectively 
control M.tb infection. Findings from animal models, as well 
as patient data, have clearly established that IFN-γ-producing 
Th1 cells play a pivotal role in host protection against TB (7–9). 
In contrast, IL-4-producing Th2 cells and regulatory T (Treg) 
cells promote disease progression by inhibiting Th1 responses 
(9–13). However, we recently showed that Stat-6−/−TGF-βRIIDN 
animals, which are devoid of Th2 cells and contain reduced 
numbers of functional Treg cells, mount exuberant inflamma-
tory Th1 responses and display suppressed bacterial burden, 
yet this response was not sufficient to induce sterile immunity 
(9). Therefore, immunotherapy directed toward promoting 
Th1-mediated inflammatory responses may not be sufficient for 
achieving sterile immunity.
The internationally accepted therapy for TB, Directly Obser-
ved Treatment Short-course (DOTS) is effective but has multiple 
serious shortfalls (1, 14–17). Even though called short-course, 
the regimen involves 6–9 months of treatment for regular TB and 
12–24  months or more for drug-resistant TB. This poses sub-
stantial risks for the generation of drug-resistant variants of the 
mycobacterial organisms. In addition, this mixture of antibiotics 
shows marked toxicity, often leading to treatment cessation by 
patients (18). Most importantly, DOTS-treated patients exhibit 
posttreatment susceptibility to reinfection and disease reactiva-
tion (19–21). It is now evident that antitubercular antibiotics 
such as isoniazid (INH) cause toxicity to antigen-activated 
T  cells during treatment, which might contribute to posttreat-
ment hypersusceptibility to disease reactivation and reinfection 
(22). Therefore, addition of an immunomodulator to antibiotic 
therapy that reduces the treatment length and restores host pro-
tective immunity is desired not only for improving the treatment 
outcome but also to reduce the possibility of generating multiple 
and extremely drug-resistant (MDR and XDR) variants of TB 
(23–25).
Tuberculosis is a complex disease with two components: 
replicating microorganisms and inflammation. Therefore, addi-
tion of anti-inflammatory drugs along with antibiotics may be 
beneficial. In fact, it has been shown that addition of steroids 
to conventional antitubercular antibiotics yields improved 
therapeutic efficacy (26). In addition, clofazimine, an inhibi-
tor of the Kv1.3 potassium channel, is an anti-inflammatory 
compound widely used for the treatment of leprosy (27–31), 
and also exhibits treatment efficacy against TB in an animal 
model (32–34). Similarly, curcumin is also an inhibitor of Kv1.3 
(35) and exhibits therapeutic benefits in several inflammatory 
and infectious diseases (36–38). Curcumin analogs have been 
reported to show promising in  vitro antimycobacterial activ-
ity against drug-resistant strains of M.tb (39, 40). Recently, 
curcumin was shown to augment mycobacterial killing in host 
macrophages by inducing apoptosis (41). In addition, curcumin 
potently inhibits hepatotoxicity (38), which is a concurrent prob-
lem in many antibiotic therapies that include TB therapy (18). 
Taken together, these data have provided strong evidence that 
curcumin is an excellent anti-inflammatory immunomodulator 
and has therapeutic potential in a variety of diseases. Despite the 
myriad of activities reported, curcumin is yet to be approved as 
a therapeutic agent due to bioavailability issues. Many clinical 
and experimental studies have clearly established that regular 
curcumin has very low bioavailability and is thus unsuitable for 
prolonged use (42, 43). Low systemic bioavailability of curcumin 
after oral dosing has been consistent throughout decades of 
studies in preclinical models as well as human clinical trials 
(44–46). This low systemic bioavailability has been attributed 
to its poor intestinal absorption, rapid metabolism, and rapid 
systemic elimination (46, 47). The plasma concentrations of cur-
cumin were found to be surprisingly low even with oral dosing 
of up to 100 mg/kg in mice (48) and 2 g/kg in rats and humans 
(49). Therefore, enhancing the bioavailability of curcumin is the 
main challenge for its applications in therapeutics.
To overcome this limitation of curcumin, we have generated 
nanoparticle-formulated curcumin adopting a simple one-step 
process, which has fivefold increased bioavailability than regular 
curcumin, and tested its efficacy in a murine TB model. We show 
that curcumin nanoparticles drastically reduce the hepatotoxicity 
induced by the antitubercular drug isoniazid (INH). Furthermore, 
curcumin nanoparticles enhanced T  cell-mediated immunity 
and prevented post-therapy susceptibility to reinfection and 
reactivation of the disease. In addition, curcumin nanoparticles 
significantly reduced the length of treatment needed for attaining 
sterile infection, and therefore is expected to reduce the risk for 
the generation of MDR and XDR variants of TB. Taken together 
these data indicate that curcumin nanoparticles are a promising 
adjunct to conventional antibiotic therapy of TB, and possibly 
other disease therapies.
MaTerials anD MeThODs
Mice
Six- to eight-week-old female BALB/c mice maintained at our 
specific pathogen-free animal facility at the International Centre 
for Genetic Engineering and Biotechnology (ICGEB, New Delhi, 
India) were used throughout the study. All animal experiments 
were conducted in accordance with guidelines approved by 
the Institutional Animals Ethics Committee (approval ID: 
ICGEB/AH/2011/2/IMM-30) of ICGEB, New Delhi, India and 
Department of Biotechnology (DBT) guidelines, Government of 
India. At the relevant times after infection with M.tb, all mice 
were humanely sacrificed by asphyxiation in carbon dioxide 
according to institutional and DBT regulations.
Preparation of curcumin nanoparticles
Four grams of curcumin (Sigma, USA) were dissolved in 1  L 
of distilled ethanol at room temperature and filtered to obtain 
a clear solution. This solution was then stirred in a high-speed 
homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 
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12,000–15,000 RPM and a required volume of Milli Q water 
containing 0.1% citric acid (Merck, India) was added to it slowly 
over a period of 30 min until the ethanol concentration became 
40% (V/V) and curcumin nanoparticles started to precipitate 
from the solution. Then the entire suspension was homogenized 
over ice in a high-pressure homogenizer (Avestin C5 High 
Pressure Homogeniser BPS, UK) at 30,000 PSI for 20 cycles. 
The aqueous suspension was then made to 0.1% polysorbate 80 
(Sigma, USA) and homogenized at 12,000–15,000 RPM (T 25 
digital ULTRA-TURRAX, IKA, USA) again for 1 h and filtered. 
The filtered slurry was dried at 60°C in an oven to get nano cur-
cumin powder. Particle size was determined by a high resolution 
transmission electron microscope (JEM 2100F, JEOL, USA).
In Vivo Bioavailability of curcumin 
nanoparticles
For determination of bioavailability, the same group of 12 female 
6- to 8-week-old BALB/c mice was used for all the experiments. 
After completion of each experiment and bleeding, the animals 
were rested for 7  days before the start of the next experiment. 
Pilot experiments were done to validate the dose to be given to 
each animal so that curcumin can be detected in the plasma. 
The method of extraction and the number of times it has to 
be extracted for near complete extraction of the analyte was 
standardized before the start of the experiment. The mice were 
given intraperitoneal injections of natural curcumin or curcumin 
nanoparticles suspended in 100  µL PBS at 100  mg/kg body 
weight in two different experiments. This dose was found to be 
the minimum dose of natural curcumin that has to be injected 
through the intraperitoneal route for detection of curcumin in 
the plasma. Therefore, it was used for both the natural curcumin 
as well as the nanoparticle-formulated curcumin experiments 
for determination of bioavailability. Blood was taken at different 
time points after intraperitoneal injection into each mouse, and 
samples were pooled, plasma was prepared for each time point, 
and curcumin was extracted using a published procedure (50). 
Briefly, 350 µL of plasma prepared from the blood collected at dif-
ferent time points from 12 female 6- to 8-week-old BALB/c mice 
injected by the intraperitoneal route with either natural curcumin 
or nanoparticle-formulated curcumin was used for extracting 
curcumin with 10 mL of a mixture of ethyl acetate (Spectrochem, 
India): isopropanol (Merck, India), 9:1 (V/V) three times. The 
organic layer was separated and dried in an oven at 60°C over a 
stream of nitrogen, and curcumin was quantified by GC-MS as 
described below.
The half-lives (T1/2) of the analytes under their respective 
experimental conditions and dosage were calculated in GraphPad 
Prism 6 software by the method of interpolating unknowns from 
a given non-linear regression based on “plateau followed by one 
phase decay” equation. For the GC-MS analyses of nanoparticle-
formulated curcumin, the dried samples were dissolved in 100 µL 
of dehydrated methanol (Sigma), vortexed, centrifuged, and 
transferred to 2 mL Agilent vials with 200 µL glass inserts. For 
the absolute quantitation, the standard curves of curcumin were 
prepared with concentration ranges of 0.025, 0.05, 1, 2, 3, 4, 5, 6, 8, 
10, and 12 mg/mL. GC-MS analysis were carried out on an Agilent 
7890A GC with Restek RTX5 capillary column (crossbond—5% 
diphenyl/95% dimethyl polysiloxane, 30 m× 0.25 mm, 0.25 µm 
film thickness) interfaced to an Agilent 7000 triple quadrupole 
mass spectrometer. The initial oven temperature was held at 60°C 
for 1 min, increased up to 180°C with a heating rate of 10°C/min; 
then the column temperature was programmed from 180 to 
300°C by a heating rate of 50°C/min and held at this temperature 
for 1 min with total runtime of 16.4 min with solvent delay of 
6 min and post runtime of 5 min. The carrier gas was He with 
a flow rate of 3  mL/min. The MS source temperature and MS 
quad temperature were adjusted to 230 and 150°C, respectively. 
Sample size injected was 1.0 µL in splitless mode. GC-MS spectra 
were recorded at 70 eV ionization voltage, and the mass range 
was from m/z 33 to 450 amu. Identification of compounds and 
interpretation of mass spectrum (GC-MS) was conducted using 
the database of National Institute of Standard and Technology.
M.tb low-Dose aerosol infection Model
This assay was performed as per the protocol described earlier by 
Tousif et al. (22).
Drug administration
50 mg/L of isoniazid (Sigma, USA) was administered ad libitum 
in drinking water daily, and 10 mg/kg body weight of curcumin 
nanoparticles suspended in 100  µL of PBS was administered 
intraperitoneally daily.
colony Forming Unit estimation
This assay was performed as per the protocol described earlier by 
Tousif et al. (22).
Flow cytometry: surface and intracellular 
staining
Spleens and lungs were isolated from mice and macerated by 
frosted slides in 10% RPMI 1640 (Gibco, Invitrogen, UK) to 
prepare a single cell suspension. We followed the protocol for 
surface and intracellular staining for flow cytometry as described 
earlier by Tousif et al. (22).
antibodies and reagents
We used the following antibodies: anti-CD4 (clone: GK1.5)-
FITC, -PerCP-Cy5, or -APC, anti-CD8 (clone: 53-6.7)-FITC, 
-PerCP-Cy5, or -APC, anti-CD44 (clone: IM7)-APC, anti-BrdU 
(clone: Bu20a)-PE, 7AAD, anti-IFN-γ (clone: XMG1.2)-APC, anti-
IL-17 (clone: TC11-18H10.1)-PE, anti-IL-4 (clone: 11B11)-PE, 
anti-IL-6 (clone: MPS-20F3)-PE, anti-IL-12 (clone: C15.6)- 
PE, anti-IL-22 (clone: Poly5164)-PE, anti-IL-10 (clone: JES5-
16E3)-PE, anti-IL-9 (clone: MH9A4)-PE, anti-TNF-α (clone: 
MP6-XT22)-PE (all from Biolegend, USA), anti-Active Caspase-3 
(clone: C92-605)-FITC or -PE (from BD Pharmingen™, USA), 
and anti-CD69 (clone: H1.2F3)-PE (from eBiosciences, USA).
In Vitro and In Vivo T cell Proliferation 
assay
These assays were performed as per the protocol described ear-
lier by Tousif et al. (22).
FigUre 1 | Physical properties and bioavailability of curcumin nanoparticles. (a) Image of curcumin nanoparticles taken with a transmission electron microscope 
(JOEL 2100F) showing particles having a size distribution of 59.9–198 nm (average size of 160 nm). (B) Dynamic light scattering of curcumin nanoparticles, showing 
unimodal size distribution with mean diameter of 213.3 nm and polydispersity index of 0.111. Analysis was performed (scattering angle = 90°, laser 
wavelength = 632.8 nm) on a 256 channel Photocor-FC (Photocor Inc., USA) operated in the multi-tau mode (logarithmically spaced channels). (c) Images of 
normal curcumin crystals having a size ranging from 1 to >20 µm, as seen by a scanning electron microscope (EM-LEO 435, Carl Zeiss SMT Inc., NY, USA).  
(D) Images of curcumin nanoparticles as seen by a scanning electron microscope (EM-LEO 435, Carl Zeiss SMT Inc., NY, USA), showing spherical morphology and 
average size of 200 nm. (e) In vivo bioavailability of curcumin nanoparticles. 100 mg/kg of natural curcumin or curcumin nanoparticles was suspended in PBS and 
injected intraperitoneally into mice. Blood was collected from these mice at different time points, plasma was prepared, and curcumin was extracted using the 
method described in Section “Materials and Methods,” and curcumin was quantitated by GC-MS for determining bioavailability.
FigUre 2 | Curcumin nanoparticles augment INH therapeutic efficacy and accelerate pathogen clearance. Mice infected with a low-dose aerosol inoculum [~110 
colony forming unit (CFU)/mice] of Mycobacterium tuberculosis H37Rv were sacrificed at various time points, and lungs were harvested, homogenized in 0.2 µm filtered 
PBS containing 0.05% Tween 80, and plated onto 7H11 Middle brook plates containing 10% oleic acid, albumin, dextrose, and catalase. Undiluted, 10-fold diluted, and 
100-fold diluted lung and spleen cell homogenates were plated in duplicate on the above 7H11 plates and incubated at 37°C for 21 days. Colonies were counted, and 
CFU was estimated. Data shown here are representative of three independent experiments. Each CFU experiment has been carried out with three mice per experiment.
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hepatotoxicity assays
Serum ALT, AST, and ALP levels were used as indicators of hepa-
totoxicity. These assays were performed by using diagnostic kits 
obtained from Span Diagnostic Limited (India) in accordance 
with the manufacturer’s protocol.
activation of OT-ii Tcr Tg T cells in the 
Presence of Ovalbumin (OVa) Peptide
Splenocytes isolated from OT-II TCR transgenic mice were 
cultured in the presence of 1  µg/mL OVA peptide along with 
1 µg/mL INH and 10 µg/mL curcumin nanoparticles for 72 h. 
FigUre 3 | Combined therapy with INH and curcumin nanoparticles induces sterile immunity that protects against recurrent disease both via reactivation or 
reinfection. (a) Treatment with curcumin nanoparticles and isoniazid provides superior sterilizing activity against latent tuberculosis when compared to conventional 
isoniazid treatment. Mice infected with Mycobacterium tuberculosis strain H37Rv following the low-dose aerosol infection model [~110 colony forming unit (CFU)/
mice] were treated with 50 mg/L isoniazid-administered ad libitum (in the drinking water) daily or 50 mg/L isoniazid-administered ad libitum along with 10 mg/kg 
body weight curcumin nanoparticles administered intraperitoneally daily until complete eradication of infection, i.e., for 75 days. These mice were then rested for 
15 days followed by dexamethasone treatment (0.8 mg/kg body weight administered intraperitoneally) three times per week for 30 days. Mice were then sacrificed, 
and CFU was analyzed from lung homogenates to estimate the reactivation of latent mycobacteria. (B) Isoniazid treatment sensitizes animals to M.tb reinfection, 
which can be overcome by combined therapy with curcumin nanoparticles. Mice infected with M.tb strain H37Rv following the low-dose aerosol infection model 
(~110 CFU/mice) were treated with 50 mg/L isoniazid-administered ad libitum daily or 50 mg/L isoniazid-administered ad libitum along with 10 mg/kg body weight 
curcumin nanoparticles administered intraperitoneally daily until after complete eradication of infection, i.e., for 60 days. These mice were then rested for 50 days 
followed by reinfection with M.tb using the same dose and protocol as for the primary infection. These mice were then sacrificed after 35 days, and lungs were 
harvested to evaluate the frequency of reinfection.
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The cells were then stained and analyzed for T  cell activation 
by FACS.
statistical analysis
All data were analyzed by Excel 2007. In all the figures, mean 
values were calculated with SD unless stated otherwise. For all 
statistical analyses Student’s t-test was performed to compare two 
groups, and p < 0.05 was considered significant.
resUlTs anD DiscUssiOn
a nanoparticle Formulation of curcumin 
extends its Bioavailability In Vivo
Curcumin is a well-known immunomodulator that is effica-
cious against several indications. However, the bioavailability 
of regular curcumin is poor and not suitable for treatment of 
diseases such as TB. Hence, we have generated a nanoparticle 
formulation of curcumin, which has a uniform size of ~200 nm 
as measured by electron microscopy (Figures  1A–D), and 
possesses an extended bioavailability (Figure  1E). Curcumin 
nanoparticles, when injected by intraperitoneal route to mice 
at 100 mg/kg body weight, showed about five times improved 
bioavailability of curcumin at 2 h postinjection with peak plasma 
concentration (CMAX) of 106 ng/mL and a half life (T1/2) of 13.1 h 
in comparison to natural curcumin which peaked at 1  h with 
CMAX of 26 ng/mL and T1/2 of 2.65 h (Figure 1E).
curcumin nanoparticles augment 
antitubercular Treatment by accelerating 
Pathogen clearance
As curcumin is an excellent immunomodulator, anti- 
inflammatory agent and antioxidant, and exhibits efficacy against 
various diseases, we sought to test if nanoparticle-formulated 
curcumin has a beneficial effect on M.tb clearance when added 
FigUre 4 | Co-treatment of curcumin nanoparticles with INH reduces inflammatory lesions in liver and hepatotoxicity caused by ATT. (a) Macroscopic pathology of 
liver at different time points after infection. Mice infected with a low-dose aerosol inoculum of Mycobacterium tuberculosis H37Rv (~110 colony forming unit/mice) 
were sacrificed 40 days postinfection, and liver was obtained and photographed to study the comparative changes in gross pathology of the liver. (B) Hepatotoxicity. 
For comparative evaluation of hepatotoxicity in the different experimental groups, we assessed serum alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and alkaline phosphatase (ALP) levels in serum at different time points. The figure shows serum ALT, AST, and ALP levels as indicators of hepatotoxicity in 
different experimental groups at 50 days postinfection.
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as an adjunct therapy. We treated M.tb infected animals with 
INH or with INH plus nanoparticle-formulated curcumin. We 
observed that curcumin nanoparticles by themselves inhibited 
the growth of H37Rv by at best 1-log in a murine model of TB, 
whereas animals treated with both curcumin nanoparticles and 
INH exhibited a dramatically accelerated clearance of the micro-
organisms in both lung and spleen (Figure 2). Moreover, cur-
cumin treatment also restored the INH-induced suppression in 
antigen-specific cytokine responses (Figure S1 in Supplementary 
Material). These observations indicated that nanoparticle-
formulated curcumin by itself is not only antimycobacterial, 
but also enhances M.tb clearance by promoting antitubercular 
immunity and thereby reduces the duration of therapy.
curcumin nanoparticles Prevent Disease 
reactivation and reinfection
From the preceding sections, it is clear that addition of curcumin 
to the conventional TB therapy dramatically enhances M.tb 
clearance by promoting antitubercular immunity. Therefore, to 
determine whether elevated antitubercular immunity promoted 
by curcumin nanoparticles helps in attaining sterile immunity 
and restores host protective memory responses we performed 
reactivation and reinfection experiments. We found that animals 
receiving adjunct treatment of curcumin nanoparticles were 
dramatically protected from reactivation of TB (Figure  3A). 
This observation suggested that addition of curcumin, an 
immunomodulator, is beneficial in attaining sterile immunity 
in the majority of subjects at a faster pace. It is highly likely 
that the heightened immune response attained by the addition 
of curcumin nanoparticles to the treatment regimen might 
have restored memory immune responses that protect animals 
from future infections. To test this possibility, we performed 
reinfection experiments. We observed that animals previously 
treated with curcumin nanoparticles are largely resistant to 
M.tb infection, indicating that a strong host protective immune 
response from the previous infection is restored. In sharp 
contrast, animals that previously received only INH displayed 
increased susceptibility to reinfection (Figure 3B). We further 
found that animals previously treated with both curcumin nano-
particles and INH exhibited drastically increased Th1 responses 
compared with animals that only received INH (Figure S2 in 
Supplementary Material). This finding is in agreement with 
recent studies demonstrating that Th1 responses are required 
FigUre 5 | T cell AICD and immune suppression induced by isoniazid can be overcome by curcumin nanoparticles. (a) Antigen-specific T cell proliferation. 
T lymphocytes were isolated from spleens of mice 40 days postinfection, and T cell proliferation assays were performed using tritiated thymidine. In vitro T cell 
proliferation of splenocytes from mice at different time points after infection was compared, after stimulation with Mycobacterium tuberculosis H37Rv complete 
soluble antigen (CSA). Data shown here are representative of five independent experiments with three mice in each group and represent the mean ± SD 
values. (B) Effect of isoniazid and curcumin nanoparticles on the activation of OT-II TCR transgenic T cells in the presence of ovalbumin (OVA) peptide. 
Splenocytes isolated from TCR Tg mice were cultured in the presence of 1 µg/mL OVA peptide along with 1 µg/mL INH and 10 µg/mL curcumin nanoparticles 
for 72 h. The cells were then stained and analyzed for T cell activation (CD44 and CD69) and cell death (7AAD) by FACS. The percentage of cells expressing 
CD44, CD69, or 7AAD among CD4+ T cells is shown with mean ± SD. Data shown here are representative of two independent experiments with two replicates 
in each group.
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and sufficient for host protective immune responses against 
M.tb infection (8).
curcumin nanoparticles Protect animals 
from inh-induced hepatotoxicity
It is well known that antitubercular antibiotics cause severe 
hepatotoxicity which results in premature therapy withdrawal 
by a large number of patients. Curcumin is an antioxidant and 
exhibits hepatoprotective properties in a variety of conditions 
(38). Therefore, we examined whether curcumin nanoparticles 
can overcome the toxicity induced by INH in our study. Our find-
ings indicated that treatment with INH causes profound toxicity 
as deduced by macroscopic analysis of liver (Figure 4A) and by 
liver enzyme levels (Figure  4B). As expected, curcumin nano-
particles dramatically reduced inflammatory lesions induced by 
infection as well as toxicity induced by INH. Taken together, 
adjunct therapy of curcumin nanoparticles is beneficial not only 
in promoting sterile immunity and inhibiting disease reactivation 
but also in preventing hepatotoxicity.
FigUre 6 | Isoniazid treatment promotes AICD in CD4 and CD8 T cells via caspase-3-mediated apoptosis, which can be controlled by combined therapy with 
curcumin nanoparticles. (a) Left panel: total number of splenocytes 40 days postinfection. Total numbers of splenocytes were counted after preparation of single 
cell suspensions using a hemocytometer. Data shown here are representative of five independent experiments with three mice in each group and represent the 
mean ± SD values. Right panel: percentage of CD4+ and CD8+ cells in spleen. Splenocytes were stained with anti-CD4 and anti-CD8 antibodies, and data were 
acquired by flow cytometry. The percentage of cells expressing CD4 and CD8 is shown in the bar diagram with mean ± SD. Data shown here are representative  
of three independent experiments with three mice in each group. (B) Effect of isoniazid and curcumin nanoparticles on the activation status of T cells in vivo. 
Splenocytes isolated from mice infected and then treated with INH or INH + CURCUMIN nanoparticles for 45 days were surface stained with anti-CD4, -CD44, and 
-CD69 antibodies, and samples were acquired by flow cytometry. CD4+ T cells were gated for CD69 expression, and the percentage of cells expressing CD69 and 
CD44 among CD4+ T cells is shown in the FACS plots with mean ± SD. Data shown here are representative of three independent experiments with three mice in 
each group. (c) In vivo T cell proliferation in spleen and lung. To study the status of host T cell proliferation in vivo during infection and treatment, 0.6 mg of BrdU in 
100 µL PBS was administered intraperitoneally to each mouse for 3 days prior to sacrifice. Cells were then isolated from both lung tissue and spleen of mice and 
stained with anti-BrdU antibodies. Data were acquired by flow cytometry. The percentage of cells showing BrdU incorporation in different groups at 40 days 
postinfection is shown in the dot-plot diagram with mean ± SD. Data shown here are representative of three independent experiments with three mice in each 
group. (D) CD4+ T cell death. Lymphocytes obtained from spleen and lung tissue of mice sacrificed 40 days postinfection were surface stained with anti-CD4 
antibodies followed by 7AAD staining for 20 min prior to acquisition. Samples were acquired by flow cytometry to assess cell death in splenocytes and alveolar 
lymphocytes. The percentage of cells expressing 7AAD among CD4+ T cells is shown with mean ± SD. Data shown here are representative of three independent 
experiments with three mice in each group. (e) Caspase-3 activation. Caspase-3 activation among CD4+ lymphocytes of lung and spleen of mice sacrificed 40 days 
postinfection was estimated by flow cytometry. Data shown here are representative of three independent experiments with three mice in each group.
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curcumin nanoparticles enhances 
antigen-specific T cell immunity
Next, we sought to examine the mechanisms by which curcumin 
nanoparticles exhibit their beneficial activities during TB treat-
ment. Previously, we have shown that prolonged use of INH 
induces apoptosis in antigen-responding T helper (Th) cells and, 
thus animals treated with INH exhibit increased susceptibility 
to M.tb reinfection and reactivation as compared with untreated 
animals (22). Similar observations have been reported in human 
studies as well (23). Therefore, we tested if co-treatment of 
curcumin nanoparticles with INH has any effects on the nature 
of the immune response in  vitro. We stimulated spleen cells 
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isolated from M.tb infected animals with M.tb derived complete 
soluble antigen in the absence or presence of INH. Surprisingly, 
we found that in the presence of INH, antigen-specific prolif-
eration of spleen cells was significantly suppressed (Figure 5A) 
and curcumin nanoparticles not only restored proliferation but 
also were capable of alleviating the INH-induced immune sup-
pression. To further investigate whether INH generally induces 
apoptosis in activated T cells, we activated OVA-specific, OT-II 
TCR transgenic T  cells with OVA peptide in the presence or 
absence of INH and curcumin nanoparticles. We observed that 
apoptosis induced by INH in activated T cells was circumvented 
by curcumin nanoparticles (Figure  5B). These observations 
indicated that curcumin nanoparticles prevent INH-induced 
immune dysfunction of T cells in vitro. Furthermore, we found 
that co-treatment with curcumin nanoparticles significantly 
reduced apoptosis in T cells (Figure 5B) and restored antigen-
specific T cell proliferation.
curcumin nanoparticles induce enhanced 
T cell responses In Vivo
To obtain insight into T cell responses in vivo, we further moni-
tored T cell responses in the murine model of TB. We tested Th 
cell frequencies in curcumin nanoparticle- and INH-treated 
animals and found that curcumin nanoparticles not only elevated 
the total number of splenocytes but also enhanced the frequency 
and activation of both CD4+ and CD8+ T cells (Figures 6A,B) 
during primary infection.
curcumin nanoparticles rescue T cells 
from inh-induced aicD
To further understand the enhanced T cell response in curcumin 
nanoparticle-treated animals, we performed BrdU incorporation 
experiments. We found that proliferation of T  cells from lung 
and spleen of INH-treated animals was profoundly suppressed 
(Figure  6C), which was restored in animals that received 
combined therapy with curcumin nanoparticle-treated mice 
(Figure  6C). Furthermore, our prior in  vitro observation that 
curcumin nanoparticles rescue T cells from cell death was also 
corroborated in the in vivo model (Figure 6D). This was most 
likely due to the capacity of curcumin to inhibit the induction 
of apoptosis in activated T  cells. To further investigate this 
hypothesis, we studied the status of activated caspase-3 in the 
T cell population. We found that curcumin nanoparticles inhibit 
the activation of caspase-3 (Figure 6E), which is critical for the 
initiation of apoptosis.
cOnclUsiOn
Irrespective of socioeconomic status, nearly all countries are 
now under threat from drug-resistant (MDR and XDR) TB (1). 
The discovery of new generations of antibiotics has lagged far 
behind in the wake of the emergence of drug resistance, and a 
totally drug-resistant form of TB has already appeared (51–54). 
Therefore, new ways to thwart the emergence of drug-resistant 
M.tb strains are urgently needed. M.tb acquires drug resistance 
predominantly due to premature treatment withdrawal by 
patients. The kinetics of M.tb clearance with DOTS treatment 
is bi-phasic. In the initial phase (~2 months) of treatment, the 
majority of the bacteria are cleared but small numbers (in the 
latent form) remain, clearance of which requires an additional 
4–6 months of treatment (1, 5, 25). During the long phase of treat-
ment, while patients are asymptomatic, patients often withdraw 
from therapy as they don’t feel the need to continue treatment. 
A second reason for treatment cessation is prolonged hepatoto-
xicity (19–21). Finally, long-term treatment does not always lead 
to complete clearance of the organisms (1).
To avoid the generation of drug-resistant strains new treat-
ments should aim at: (i) shortening the treatment course; 
(ii) attaining sterile immunity; and (iii) reducing hepatoto xicity. 
Curcumin is an excellent immunomodulator that promotes 
antimycobacterial immunity, thereby reducing the length of 
treatment when combined with conventional antibiotics. This 
reduction in length of treatment may reduce the possibility for 
generating drug-resistant variants of TB. Furthermore, elevated 
immunity helps in attaining complete clearance much faster, 
which is further beneficial in reducing the possibility of disease 
reactivation.
Curcumin is an anti-inflammatory agent that exhibits efficacy 
against several inflammatory and infectious diseases. However, 
bioavailability of curcumin and metabolic instability under 
physiologic conditions has hindered its use as a drug. Therefore 
nanotechnology-based novel drug delivery methods show prom-
ise to overcome these challenges. Polymeric nanoparticle-based 
encapsulation of curcumin (55) or nanoliposome-encapsulated 
forms of curcumin (56) have been successfully generated. 
Although such formulations of curcumin have been successfully 
delivered into cells in  vitro, loading curcumin onto nanoparti-
cles or trapping curcumin inside of liposomes followed by its 
controlled release at the desired tissue site has been challenging. 
In addition, toxicity arising from the long-term use of such 
formulations of curcumin in vivo has not yet been reported. We 
have therefore used pure curcumin to prepare our nanoparticles, 
which is chemically identical to natural curcumin as both of 
them had similar HPLC and NMR profile. However, it is about 
five times more bioavailable (CMAX) and circulates for a longer 
period of time in the blood (T1/2). Curcumin, being non-toxic, 
can be given up to 8  g/day to humans (47, 57). Therefore this 
nanoparticle formulation of curcumin could be used in human 
subjects at very high doses. Our curcumin nanoparticles are stable 
and can be administered both orally as well as intraperitoneally 
and, therefore, have greater potential for therapeutic use under 
different conditions.
Tuberculosis is a disease with two components, such as micro-
bial infection and inflammation. Therefore, addition of steroids to 
the conventional antibiotic treatment regimen displays improved 
efficacy (58). Steroids have several limitations and, therefore, 
curcumin may serve as both an immunomodulator and an anti-
inflammatory agent, which might aid in reducing the length of 
treatment. Previously, we have demonstrated that antitubercular 
antibiotics eliminate antigen-responding T cells during treatment 
leaving animals hyper-susceptible to reinfection (22). This is 
consistent with the finding that patients treated with antibiot-
ics are hypersusceptible to disease reactivation and reinfection 
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(23, 24). Curcumin prevented apoptosis in antigen-responding 
T  cells induced by antibiotics and would thus be expected to 
promote improved memory responses upon completion of 
combined therapy. Interestingly, curcumin is an inhibitor of 
Kv1.3 (35), which is predominantly expressed by effector memory 
T (TEM) cells (59, 60). Recently, we have shown that inhibition 
of Kv1.3 by clofazimine dramatically enhances the generation 
of central memory T (TCM) cells, a subset of memory T cells that 
dictate prolonged efficacy of a vaccine by inhibiting Tem cells 
(61). Similarly, inhibition of Kv1.3 by curcumin may contribute 
toward host protection against TB reinfection by expanding the 
TCM population.
Current antibiotics used in DOTS therapy are toxic, which 
is a major clinical cause of treatment cessation that can contrib-
ute to the generation of drug-resistant TB (15, 51, 52, 62, 63). 
Curcumin has been shown to alleviate hepatotoxicity in various 
situations (38). In our study, we also found that combined treat-
ment of nanoparticle-formulated curcumin drastically inhibited 
hepatotoxicity induced by antibiotics. Therefore, addition of cur-
cumin along with conventional antibiotics provides additional 
benefit in reducing hepatotoxicity.
Addition of an immunomodulator to conventional antibiotic 
therapy has beneficial effects in the treatment of TB (64) and 
has been recommended for effective treatment. Curcumin is an 
excellent immunomodulator that reduces the length of treatment 
and helps in attaining sterile immunity when combined with 
conventional antibiotics. Furthermore, it prevents apoptosis of 
antigen-responding T  cells and heightens memory T  cell res-
ponses during treatment. As curcumin is an inhibitor of Kv1.3, 
it alters the ratio of TCM:TEM, which provides protection against 
posttreatment infection. In addition, curcumin inhibits hepa-
totoxicity induced by antibiotics. These beneficial features of 
curcumin are directed to the host, and its implications are there-
fore not limited to M.tb infection. Taken together, our findings 
raise enthusiasm for initiating clinical trials to test the safety and 
efficacy of curcumin nanoparticles as an adjuvant for treatment 
of TB and other diseases.
summary
We generated curcumin nanoparticles, which have a uniform size 
of ~200 nm and showed extended bioavailability in vivo. These 
curcumin nanoparticles were not only antimycobacterial but also 
enhanced M.tb clearance by promoting antitubercular immunity 
and thereby reduced the duration of therapy required to achieve 
sterility. Curcumin nanoparticles induced heightened T  cell 
immunity, which prevented disease reactivation and reinfection. 
Adjunct therapy of curcumin nanoparticles not only promoted 
sterile immunity and prevented disease reactivation but also 
resulted in preventing hepatotoxicity, thereby making it a very 
suitable adjunct for TB therapy.
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FigUre s1 | INH suppresses cytokine production by splenocytes. Splenocytes 
were cultured and activated with 50 ng/ml phorbol 12-myristate 13-acetate and 
750 ng/ml ionomycin overnight, and 10 µg/ml Brefeldin A was added during the 
last 6 h of culture. Cells were then intracellularly stained with anti-IL4, -IFN-γ, 
-IL17, -IL9, -IL10, -IL12, -TNF-α, -IL6, or -IL22 antibodies and appropriately 
labeled control antibodies. Cells were acquired by a flow cytometer. Data are 
shown as mean ± SD, and Student’s t-test was done for estimating significance 
between two groups.
FigUre s2 | Cytokine production by splenocytes from treated mice that were 
reinfected with Mycobacterium tuberculosis. Splenocytes were cultured and 
activated with 50 ng/ml phorbol 12-myristate 13-acetate and 750 ng/ml 
ionomycin overnight, and 10 µg/ml Brefeldin A was added during the last 6 h of 
culture. Cells were then intracellularly stained with anti-IL4, -IFN-γ, -IL17, -IL9, 
-IL10, -IL12, -TNF-α, -IL6, and -IL22 antibodies and appropriately labeled control 
antibodies. Cells were acquired by a flow cytometer. Data are shown as 
mean ± SD, and Student’s t-test was done for estimating significance between 
two groups.
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